Welcome to our dedicated page for Telomir Pharms news (Ticker: TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharms stock.
Telomir Pharmaceuticals Inc (TELO) is a preclinical-stage biotech leader developing Telomir-1, an innovative therapy targeting cellular aging through telomere lengthening and oxidative stress management. This page provides investors and researchers with essential updates on the company’s scientific advancements, regulatory progress, and strategic initiatives.
Access authoritative reports on clinical trial developments, research collaborations, and financial updates directly tied to TELO’s mission to address age-related diseases. Our curated news collection covers key areas including preclinical study results, intellectual property milestones, and partnerships in longevity science.
Stay informed about Telomir’s pioneering work in metal ion regulation and telomere biology through verified press releases and objective analysis. Bookmark this page for real-time updates on breakthroughs in treating conditions like Alzheimer’s, diabetes, and progeria via TELO’s novel therapeutic approach.
Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, has been added to the Russell 3000 and Russell Microcap Indexes as of July 1, 2024.
This inclusion follows the annual Russell indexes reconstitution, which ranks the 4,000 largest US stocks by market capitalization. Membership in these indexes signifies automatic inclusion in either the Russell 1000 or Russell 2000 indexes, impacting index funds and active investment strategies.
FTSE Russell manages these indexes, which benchmark approximately $10.5 trillion in assets. Telomir's CEO, Dr. Chris Chapman, highlighted this milestone as evidence of the company's progress since its IPO in February and its commitment to advancing Telomir-1, a potential treatment for age-related conditions.
Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, announced the participation of its scientific advisor, Dr. Adam Kaplin, in the Drug Information Association (DIA) 2024 Global Annual Meeting on June 17, 2024. The event, being the largest global gathering for professionals in pharmaceuticals, biotechnology, and medical devices, will feature Dr. Kaplin in a panel discussion on generative AI in clinical trials. He will discuss how AI-powered data modeling can significantly reduce time and cost in therapeutic studies while maintaining high patient safety standards. This approach has the potential to expedite drug dosing, trial performance, and patient safety by up to 90%.
Telomir Pharmaceuticals (Nasdaq: TELO) announced significant milestones for its lead product candidate, Telomir-1. The Company began a pivotal study on May 28, 2024, to evaluate the safety and efficacy of Telomir-1 in geriatric laboratory Beagle dogs over 63 days. The initial dosing was well-tolerated by all animals, aiming to treat age-related conditions like gait weakness and joint damage. Additionally, Telomir is treating a 12-year-old German Shepherd named Zeus with Telomir-1, gathering real-world data for future research and regulatory efforts. These studies are key steps towards developing treatments for both veterinary and human age-related diseases.
FAQ
What is the current stock price of Telomir Pharms (TELO)?
What is the market cap of Telomir Pharms (TELO)?
